Cargando…
A comprehensive metabolic profiling of the metabolically healthy obesity phenotype
BACKGROUND: The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as “metabolically healthy obese” (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211343/ https://www.ncbi.nlm.nih.gov/pubmed/32386512 http://dx.doi.org/10.1186/s12944-020-01273-z |
_version_ | 1783531437778010112 |
---|---|
author | Telle-Hansen, Vibeke H. Christensen, Jacob J. Formo, Gulla Aase Holven, Kirsten B. Ulven, Stine M. |
author_facet | Telle-Hansen, Vibeke H. Christensen, Jacob J. Formo, Gulla Aase Holven, Kirsten B. Ulven, Stine M. |
author_sort | Telle-Hansen, Vibeke H. |
collection | PubMed |
description | BACKGROUND: The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as “metabolically healthy obese” (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite this, the MHO phenotype is still sub-optimally characterized with respect to a comprehensive risk assessment. Our aim was to increase the understanding of metabolic alterations associated with healthy and unhealthy obesity. METHODS: In this cross-sectional study, men and women (18–70 years) with obesity (body mass index (BMI) ≥ 30 kg/m(2)) or normal weight (NW) (BMI ≤ 25 kg/m(2)) were classified with MHO (n = 9), MUO (n = 10) or NW (n = 11) according to weight, lipid profile and glycemic regulation. We characterized individuals by comprehensive metabolic profiling using a commercial available high-throughput proton NMR metabolomics platform. Plasma fatty acid profile, including short chain fatty acids, was measured using gas chromatography. RESULTS: The concentrations of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) subclasses were overall significantly higher, and high density lipoprotein (HDL) subclasses lower in MUO compared with MHO. VLDL and IDL subclasses were significantly lower and HDL subclasses were higher in NW compared with MHO. The concentration of isoleucine, leucine and valine was significantly higher in MUO compared with MHO, and the concentration phenylalanine was lower in NW subjects compared with MHO. The fatty acid profile in MHO was overall more favorable compared with MUO. CONCLUSIONS: Comprehensive metabolic profiling supports that MHO subjects have intermediate-stage cardiovascular disease risk marker profile compared with NW and MUO subjects. CLINICAL TRIAL REGISTRATION NUMBER: NCT01034436, Fatty acid quality and overweight (FO-study). GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-7211343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72113432020-05-14 A comprehensive metabolic profiling of the metabolically healthy obesity phenotype Telle-Hansen, Vibeke H. Christensen, Jacob J. Formo, Gulla Aase Holven, Kirsten B. Ulven, Stine M. Lipids Health Dis Research BACKGROUND: The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as “metabolically healthy obese” (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite this, the MHO phenotype is still sub-optimally characterized with respect to a comprehensive risk assessment. Our aim was to increase the understanding of metabolic alterations associated with healthy and unhealthy obesity. METHODS: In this cross-sectional study, men and women (18–70 years) with obesity (body mass index (BMI) ≥ 30 kg/m(2)) or normal weight (NW) (BMI ≤ 25 kg/m(2)) were classified with MHO (n = 9), MUO (n = 10) or NW (n = 11) according to weight, lipid profile and glycemic regulation. We characterized individuals by comprehensive metabolic profiling using a commercial available high-throughput proton NMR metabolomics platform. Plasma fatty acid profile, including short chain fatty acids, was measured using gas chromatography. RESULTS: The concentrations of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) subclasses were overall significantly higher, and high density lipoprotein (HDL) subclasses lower in MUO compared with MHO. VLDL and IDL subclasses were significantly lower and HDL subclasses were higher in NW compared with MHO. The concentration of isoleucine, leucine and valine was significantly higher in MUO compared with MHO, and the concentration phenylalanine was lower in NW subjects compared with MHO. The fatty acid profile in MHO was overall more favorable compared with MUO. CONCLUSIONS: Comprehensive metabolic profiling supports that MHO subjects have intermediate-stage cardiovascular disease risk marker profile compared with NW and MUO subjects. CLINICAL TRIAL REGISTRATION NUMBER: NCT01034436, Fatty acid quality and overweight (FO-study). GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-05-09 /pmc/articles/PMC7211343/ /pubmed/32386512 http://dx.doi.org/10.1186/s12944-020-01273-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Telle-Hansen, Vibeke H. Christensen, Jacob J. Formo, Gulla Aase Holven, Kirsten B. Ulven, Stine M. A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title | A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title_full | A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title_fullStr | A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title_full_unstemmed | A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title_short | A comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
title_sort | comprehensive metabolic profiling of the metabolically healthy obesity phenotype |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211343/ https://www.ncbi.nlm.nih.gov/pubmed/32386512 http://dx.doi.org/10.1186/s12944-020-01273-z |
work_keys_str_mv | AT tellehansenvibekeh acomprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT christensenjacobj acomprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT formogullaaase acomprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT holvenkirstenb acomprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT ulvenstinem acomprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT tellehansenvibekeh comprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT christensenjacobj comprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT formogullaaase comprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT holvenkirstenb comprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype AT ulvenstinem comprehensivemetabolicprofilingofthemetabolicallyhealthyobesityphenotype |